Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn’s Disease: The Toronto Consensus
A. Hillary Steinhart(Mount Sinai Hospital), Chadwick Williams, Çharles N. Bernstein(University of Manitoba), Greg Rosenfeld(British Columbia Centre on Substance Use), Waqqas Afif, Mark Borgaonkar, John K. Marshall(McMaster University), Reena Khanna(University of Toronto), Alain Bitton(McGill University Health Centre), Grigorios I. Leontiadis(McMaster University), Laura E. Targownik(University of Manitoba), Paul Moayyedi(McMaster University Medical Centre), Edward V. Loftus(Mayo Clinic), Sanjay K. Murthy(University of Ottawa), Brian Bressler(University of British Columbia), Jennifer Jones(Dalhousie University), Erin Kennedy(Mount Sinai Hospital), Cynthia H. Seow(University of Calgary), Sophie Plamondon(Université de Sherbrooke), Brendan P. Halloran(University of Alberta), Usha Chauhan(Hamilton Health Sciences), David A. Schwartz(St. Jude Children's Research Hospital), Jonathan B. Meddings(University of Calgary), Remo Panaccione(University of Calgary)
Cited by 19
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
A Genome-Wide Association Study Identifies <i>IL23R</i> as an Inflammatory Bowel Disease Gene
|Science|2006|3k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target
|The American Journal of Gastroenterology|2015|1.8k